NEW YORK (TheStreet) -- BioCryst Pharmaceuticals (BCRX) rose Tuesday after the company announced its experimental drug for treating a rare immune disorder was effective in decreasing the disease's attacks in a mid-stage trial.
The trial compared the drug, BCX4161, to a placebo and tested it in patients with hereditary angioedema (HAE), a genetic disease that manifests with sudden attacks of swelling of the skin or the mucous membranes. The attacks can disfigure, cause pain and could even threaten patients' lives.
The results showed those treated with the drug had an average of 0.82 attacks per week, compared to 1.27 attacks per week for those given a placebo.
Must Read: Warren Buffett's 25 Favorite StocksSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. The stock was up 8.83% to $9.80 at 11:17 a.m. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts